Related Experiment Video
Updated: Aug 15, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Evidence for the Use of Steroidal Aldosterone Antagonists in Patients With Kidney Failure
Panagiotis I Georgianos1, Anastasios Kollias2, Athanasios Roumeliotis1
12(nd) Department of Nephrology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Abstract:
Although mineralocorticoid receptor (MR) antagonism is a mechanistically plausible target of therapy in patients with kidney failure, prior small trials failed to elucidate the safety and efficacy of spironolactone and eplerenone in this population. More conclusive evidence was provided by the ALCHEMIST and ACHIEVE trials, in which spironolactone was not superior to placebo in improving cardiovascular outcomes in patients with kidney failure. The incidence of moderate hyperkalemia in these trials was higher with spironolactone than with placebo. Accordingly, the use of spironolactone or eplerenone for cardiovascular protection in this population is not justified by the currently available clinical-trial data.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Potassium-Sparing Diuretics
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Antihypertensive Drugs: Angiotensin II Receptor Blockers